Date | Price Target | Rating | Analyst |
---|---|---|---|
5/7/2024 | $12.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
5/7/2024 | $10.00 → $0.50 | Buy → Hold | Jefferies |
5/7/2024 | Buy → Underperform | BofA Securities | |
5/6/2024 | Outperform → Mkt Perform | William Blair | |
10/6/2023 | $15.00 | Buy | BTIG Research |
8/31/2023 | $12.00 | Buy | H.C. Wainwright |
5/24/2022 | $15.00 | Overweight | Cantor Fitzgerald |
SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12036337
In the latest quarter, 4 analysts provided ratings for Lyra Therapeutics (NASDAQ:LYRA), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 2 0 0 Last 30D 0 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 2 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.38, with a high estimate of $12.00 and a low estimate of $0.50. A negative shift in sentiment is evident as analysts ha
Cantor Fitzgerald analyst Louise Chen reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Overweight.
H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously
Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously
BofA Securities downgraded Lyra Therapeutics from Buy to Underperform
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps – WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusi
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under Lyra's 2022 Employment Inducement Award Plan, as amende
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under the Company's 2022 Inducement Award Plan, as amended, and related form
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
10-Q - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)